Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Resolves Ovation Sabril Conflict Of Interest; Sets Jan. 7-8 Advisory Panel Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Peripheral and CNS Drugs Advisory Committee to consider two indications for Sabril: to treat infantile spasms and as adjunctive therapy for refractory complex partial seizures in adults.

You may also be interested in...

The Longest Review: Inside Ovation’s Wait For Sabril

The anticonvulsant vigabatrin is one of a dozen products for which FDA has missed user fee deadlines so far this year. Fifteen years after the NDA first was submitted, maybe that shouldn’t be a surprise.

Advisory Committee Conflict Of Interest Policy More Flexible In Final Form

FDA releases slew of committee-related guidances, including draft on the criteria to determine when a committee meeting should be held.

FDA Panel To Review Ovation’s Sabril For Dual Epilepsy Indications

Vigabatrin set for review by Peripheral and Central Nervous System Drugs panel for seizures in adults and infantile spasms Aug. 6-7.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts